Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
about
Amphetamine, past and present--a pharmacological and clinical perspectiveAddiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulantsPharmacotherapy of amphetamine-type stimulant dependence: an updateMethamphetamine increases LPS-mediated expression of IL-8, TNF-α and IL-1β in human macrophages through common signaling pathwaysAmphetamine elicits opposing actions on readily releasable and reserve pools for dopamineCocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activationPharmacotherapeutic agents in the treatment of methamphetamine dependence.Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering ratsA tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.HIV-1 gp120 and drugs of abuse: interactions in the central nervous systemMethamphetamine toxicity and its implications during HIV-1 infection.Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.Methamphetamine influences on brain and behavior: unsafe at any speed?Striatal dopamine neurotransmission: regulation of release and uptakeVMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discriminationPsychostimulants and movement disorders.Clinical aspects and management of levodopa-induced dyskinesia.The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice.Ephedrine decreases vesicular monoamine transporter-2 function.Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine releaseHIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomesLipid peroxidation and apoptotic response in rat brain areas induced by long-term administration of nandrolone: the mutual crosstalk between ROS and NF-kBN-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.Methamphetamine self-administration acutely decreases monoaminergic transporter function.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Endogenous 5-HT outflow from chicken aorta by 5-HT uptake inhibitors and amphetamine derivatives.A Comprehensive View of the Neurotoxicity Mechanisms of Cocaine and Ethanol.The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects.Controlled cortical impact injury influences methylphenidate-induced changes in striatal dopamine neurotransmission.Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.Running wheel exercise before a binge regimen of methamphetamine does not protect against striatal dopaminergic damage.Comparison of single-dose and extended methamphetamine administration on reversal learning in rats.Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway.A partial trace amine-associated receptor 1 agonist exhibits properties consistent with a methamphetamine substitution treatment.Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats.
P2860
Q22241826-910A847D-0035-4BD6-B3D2-8E2B2B2AC4E2Q22251215-598B30F5-FE81-4FC0-AA08-7263ACB1C6EBQ26991936-32CB2C90-14DC-4EC9-8630-FBBD96AA160AQ28481873-44E1BF97-6E94-4F59-B0C2-A724687D86ADQ28487647-2CB403C9-BF8C-45D4-B51C-8466C3395370Q28576129-19BE1BD6-BB47-4ACD-B717-AA8EB2123BBEQ30235058-A6C27484-DC37-4005-A344-38DDC276C386Q30443801-FA39B4EA-7D5B-4EC3-85AF-70E9F6B1EA23Q33625390-CD38425F-3639-4A08-9E85-D58636C06317Q33714937-4C9643FD-8635-45C3-8452-DF0C56682C8BQ33747909-F3C16A99-67B9-4B37-BD14-732F7FCC07E3Q33861553-C0D005EC-EF3D-411B-83CA-B9D7707609D1Q33985461-16E119A4-1D94-4AAE-8AB4-9BA09F2ECFC9Q34214699-576D079F-B42B-4C41-905D-253751DB342BQ34282453-39DFE9D4-1BC4-4FB4-B171-AEB2D3B57007Q34524803-43B072FB-2D94-4F1B-9E1D-1B7B12C3F50BQ35191319-C1F35115-5998-402B-AF4D-38364BFA7F70Q35489276-A441F447-E0A3-4C38-98B9-AEDC7D6B465DQ36022700-4185EE57-3C74-4050-AF7F-847E8816B555Q36079830-C98992D1-0550-46E8-821F-DBCA2B7DCB38Q36216477-188D2D2E-490E-4EA9-96A7-972CE04890FCQ36537878-2CA9F0CF-B585-450E-9C60-8C26E5AEAC55Q36537895-CFA40ADC-04A5-43A2-A824-8D6353EA168BQ36537905-8A8C7726-F283-4130-BFDC-481921077F6CQ36944251-D3A7F69F-BA51-4DA1-9216-7DC0F8EFAFA8Q37446868-B480209E-EEBD-45D0-B91C-348995536CB6Q37589110-55874129-BE10-4B6F-A58E-3D0E4C9703C9Q37656152-E61698F1-EB95-4CBB-8BF9-A01C0110B7FAQ37924629-86D32090-9765-4844-807A-364D9018ABBDQ38372945-AB087E63-6AB6-4107-9E96-A13567A00897Q38536415-489E3C02-7E92-42F8-A534-81ABB9EC0FB8Q41240710-A94CD073-0908-4FB5-8987-EF602756306BQ42099064-38F30283-8F72-4355-8F9A-0CE5B953AF5FQ42128651-719CBAB1-77D8-46AA-BBCE-7E8179BA82DEQ45178969-353DEDB7-F48E-4120-99D7-EAD1F4D32938Q46163907-714F7F9E-C880-4920-AC3F-9070913E0031Q46252209-C75F02F0-271C-4076-BCA2-50D1BA4C0733Q47427258-4090F163-948C-4D23-97B1-EFD5DADEE920Q48121473-EBE0F039-D865-4904-9F39-7AC86EC82D91
P2860
Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Psychostimulant-induced altera ...... and therapeutic implications.
@en
Psychostimulant-induced altera ...... and therapeutic implications.
@nl
type
label
Psychostimulant-induced altera ...... and therapeutic implications.
@en
Psychostimulant-induced altera ...... and therapeutic implications.
@nl
prefLabel
Psychostimulant-induced altera ...... and therapeutic implications.
@en
Psychostimulant-induced altera ...... and therapeutic implications.
@nl
P2093
P2860
P1433
P1476
Psychostimulant-induced altera ...... and therapeutic implications.
@en
P2093
Annette E Fleckenstein
Glen R Hanson
Trent J Volz
P2860
P304
P356
10.1016/J.NEUROPHARM.2008.07.002
P478
56 Suppl 1
P577
2008-07-10T00:00:00Z